• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Osteoporosis: Romosozumab to rebuild the foundations of bone strength.

作者信息

Ferrari Serge L

机构信息

Service and Laboratory of Bone Diseases, Geneva University Hospital, 1205 Geneva, Switzerland.

出版信息

Nat Rev Rheumatol. 2018 Mar;14(3):128. doi: 10.1038/nrrheum.2018.5. Epub 2018 Jan 25.

DOI:10.1038/nrrheum.2018.5
PMID:29367691
Abstract
摘要

相似文献

1
Osteoporosis: Romosozumab to rebuild the foundations of bone strength.骨质疏松症：使用罗莫单抗重建骨强度基础。
Nat Rev Rheumatol. 2018 Mar;14(3):128. doi: 10.1038/nrrheum.2018.5. Epub 2018 Jan 25.
2
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.罗莫佐单抗或阿仑膦酸钠用于预防骨质疏松症女性骨折。
N Engl J Med. 2017 Oct 12;377(15):1417-1427. doi: 10.1056/NEJMoa1708322. Epub 2017 Sep 11.
3
Romosozumab versus Alendronate and Fracture Risk in Women with Osteoporosis.罗莫单抗与阿仑膦酸钠及骨质疏松症女性骨折风险的研究
N Engl J Med. 2018 Jan 11;378(2):195-196. doi: 10.1056/NEJMc1714810.
4
Romosozumab versus Alendronate and Fracture Risk in Women with Osteoporosis.罗莫单抗与阿仑膦酸钠对骨质疏松症女性骨折风险的影响比较
N Engl J Med. 2018 Jan 11;378(2):194. doi: 10.1056/NEJMc1714810.
5
Romosozumab versus Alendronate and Fracture Risk in Women with Osteoporosis.罗莫单抗与阿仑膦酸钠及骨质疏松症女性骨折风险的比较
N Engl J Med. 2018 Jan 11;378(2):194-5. doi: 10.1056/NEJMc1714810.
6
Romosozumab versus Alendronate and Fracture Risk in Women with Osteoporosis.罗莫佐单抗与阿仑膦酸钠及骨质疏松症女性骨折风险的比较
N Engl J Med. 2018 Jan 11;378(2):195. doi: 10.1056/NEJMc1714810.
7
Bone diseases: Romosozumab - on track or derailed?骨骼疾病：罗莫司单抗——按计划进行还是脱轨？
Nat Rev Endocrinol. 2017 Dec;13(12):697-698. doi: 10.1038/nrendo.2017.136. Epub 2017 Oct 13.
8
In postmenopausal women with osteoporosis, romosozumab followed by alendronate reduced fractures vs alendronate alone.在患有骨质疏松症的绝经后女性中，先使用罗莫单抗然后使用阿仑膦酸钠比单独使用阿仑膦酸钠能降低骨折发生率。
Ann Intern Med. 2018 Jan 16;168(2):JC3. doi: 10.7326/ACPJC-2018-168-2-003.
9
Romosozumab for the treatment of osteoporosis.罗莫佐单抗用于治疗骨质疏松症。
Expert Opin Biol Ther. 2017 Feb;17(2):255-263. doi: 10.1080/14712598.2017.1280455.
10
Cardiovascular Outcomes of Romosozumab and Protective Role of Alendronate.罗莫佐单抗的心血管结局和阿仑膦酸钠的保护作用。
Arterioscler Thromb Vasc Biol. 2019 Jul;39(7):1343-1350. doi: 10.1161/ATVBAHA.119.312371. Epub 2019 May 23.

引用本文的文献

1
Development of a novel macroscopic regulation and microscopic intervention mode nanosystem for osteoporosis treatment.一种用于骨质疏松症治疗的新型宏观调控与微观干预模式纳米系统的研发。
Mater Today Bio. 2025 May 1;32:101829. doi: 10.1016/j.mtbio.2025.101829. eCollection 2025 Jun.
2
Comparative Analysis of Romosozumab Versus Vertebroplasty With Denosumab: Efficacy, Safety, and Secondary Bone Mineral Density Outcomes.罗莫单抗与地诺单抗联合椎体成形术的对比分析：疗效、安全性及继发性骨矿物质密度结果
Neurospine. 2025 Mar;22(1):69-77. doi: 10.14245/ns.2449228.614. Epub 2025 Mar 31.
3
First-line treatment of osteoporosis with osteoanabolic therapy: a new opportunity.

本文引用的文献

1
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.罗莫佐单抗或阿仑膦酸钠用于预防骨质疏松症女性骨折。
N Engl J Med. 2017 Oct 12;377(15):1417-1427. doi: 10.1056/NEJMoa1708322. Epub 2017 Sep 11.
2
Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial.罗莫佐单抗（硬骨素单克隆抗体）与特立帕肽在口服双膦酸盐治疗后绝经后骨质疏松症女性中的比较：一项随机、开放标签、3 期临床试验。
Lancet. 2017 Sep 30;390(10102):1585-1594. doi: 10.1016/S0140-6736(17)31613-6. Epub 2017 Jul 26.
3
采用骨合成代谢疗法对骨质疏松症进行一线治疗：一个新机遇。
Intern Med J. 2025 Aug;55(8):1232-1241. doi: 10.1111/imj.70061. Epub 2025 Apr 9.
4
Treatment effects, adverse outcomes and cardiovascular safety of romosozumab - Existing worldwide data: A systematic review and meta-analysis.罗莫单抗的治疗效果、不良结局及心血管安全性——全球现有数据：一项系统评价与荟萃分析
J Orthop Translat. 2024 Aug 3;48:107-122. doi: 10.1016/j.jot.2024.07.011. eCollection 2024 Sep.
5
Immunohistochemical and Morphometric Assessment on the Biological Function and Vascular Endothelial Cells in the Initial Process of Cortical Porosity in Mice With PTH Administration.甲状旁腺激素给药小鼠皮质骨多孔形成初始过程中的生物学功能和血管内皮细胞的免疫组织化学和形态计量评估。
J Histochem Cytochem. 2024 May;72(5):309-327. doi: 10.1369/00221554241247883. Epub 2024 May 10.
6
Prevotella histicola Prevented Particle-Induced Osteolysis via Gut Microbiota-Dependent Modulation of Inflammation in Ti-Treated Mice.牙龈卟啉单胞菌通过调节肠道菌群依赖的炎症反应预防钛颗粒诱导的骨溶解。
Probiotics Antimicrob Proteins. 2024 Apr;16(2):383-393. doi: 10.1007/s12602-023-10057-7. Epub 2023 Mar 10.
7
Exploratory use of romosozumab for osteoporosis in a patient with Hajdu-Cheney syndrome: a case report.哈杰-切尼综合征患者骨质疏松应用罗莫佐单抗的探索性治疗：病例报告。
Osteoporos Int. 2023 May;34(5):1005-1009. doi: 10.1007/s00198-023-06668-z. Epub 2023 Jan 9.
8
Clinical Utility of Romosozumab in the Management of Osteoporosis: Focus on Patient Selection and Perspectives.罗莫索单抗在骨质疏松症管理中的临床应用：聚焦患者选择与展望
Int J Womens Health. 2022 Dec 15;14:1733-1747. doi: 10.2147/IJWH.S315184. eCollection 2022.
9
Spatiotemporal Analysis of Osteoblast Morphology and Wnt Signal-Induced Osteoblast Reactivation during Bone Modeling in Vitro.体外骨建模过程中破骨细胞形态及Wnt信号诱导破骨细胞再激活的时空分析
JBMR Plus. 2022 Oct 21;6(11):e10689. doi: 10.1002/jbm4.10689. eCollection 2022 Nov.
10
Cardiovascular Safety of Anti-Sclerostin Therapy in Chronic Kidney Disease.抗硬化蛋白疗法在慢性肾脏病中的心血管安全性
Metabolites. 2021 Nov 10;11(11):770. doi: 10.3390/metabo11110770.
10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.
10 年地舒单抗治疗绝经后骨质疏松症妇女：来自 3 期随机 FREEDOM 试验和开放标签扩展的结果。
Lancet Diabetes Endocrinol. 2017 Jul;5(7):513-523. doi: 10.1016/S2213-8587(17)30138-9. Epub 2017 May 22.
4
Romosozumab Treatment in Postmenopausal Osteoporosis.罗莫单抗治疗绝经后骨质疏松症
N Engl J Med. 2017 Jan 26;376(4):396-7. doi: 10.1056/NEJMc1615367.
5
Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.阿巴洛肽与安慰剂对绝经后骨质疏松症妇女新发椎体骨折的影响：一项随机临床试验。
JAMA. 2016 Aug 16;316(7):722-33. doi: 10.1001/jama.2016.11136.
6
Bisphosphonates for cardiovascular risk reduction: A systematic review and meta-analysis.双膦酸盐类药物降低心血管风险：系统评价和荟萃分析。
Atherosclerosis. 2016 Sep;252:106-115. doi: 10.1016/j.atherosclerosis.2016.06.039. Epub 2016 Jun 24.
7
Sustained Modeling-Based Bone Formation During Adulthood in Cynomolgus Monkeys May Contribute to Continuous BMD Gains With Denosumab.成年食蟹猴基于模型的持续骨形成可能有助于地诺单抗治疗下骨密度的持续增加。
J Bone Miner Res. 2015 Jul;30(7):1280-9. doi: 10.1002/jbmr.2480.
8
Romosozumab in postmenopausal women with low bone mineral density.罗莫佐单抗治疗绝经后低骨密度妇女。
N Engl J Med. 2014 Jan 30;370(5):412-20. doi: 10.1056/NEJMoa1305224. Epub 2014 Jan 1.
9
Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases.骨疾病中骨硬化蛋白和 Dickkopf-1 作为治疗靶点。
Endocr Rev. 2012 Oct;33(5):747-83. doi: 10.1210/er.2011-1060. Epub 2012 Jun 20.
10
Denosumab and bisphosphonates: different mechanisms of action and effects.地舒单抗和双膦酸盐：不同的作用机制和效果。
Bone. 2011 Apr 1;48(4):677-92. doi: 10.1016/j.bone.2010.11.020. Epub 2010 Dec 9.